Following validation of the developed PBPK model in healthy subjects, the model was applied to predict the pharmacokinetic profiles of CYP3A4 and CYP2C19 substrate drugs after intravenous or oral administration in 1000 virtual patients with cirrhosis (Figure 5). This evidence concerns the gene CYP3A4 and Cirrhosis.